Status:
COMPLETED
Retinoblastoma Biomarker Study
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Retinoblastoma
Melanoma
Eligibility:
All Genders
7+ years
Brief Summary
Retinoblastoma is a rare pediatric ocular tumor caused by germline and/or somatic mutations in the tumor suppressor gene RB1. Survivors of retinoblastoma, particularly those with the hereditary form o...
Detailed Description
Retinoblastoma is a rare pediatric ocular tumor caused by germline and/or somatic mutations in the tumor suppressor gene RB1. Survivors of retinoblastoma, particularly those with the hereditary form o...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Children treated for retroblastoma over the past 30-plus years.
Exclusion
Key Trial Info
Start Date :
November 17 1993
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 6 2024
Estimated Enrollment :
2136 Patients enrolled
Trial Details
Trial ID
NCT00342797
Start Date
November 17 1993
End Date
March 6 2024
Last Update
March 7 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892
2
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States, 02114-3096
3
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
4
Social Scientific Systems, Inc.
Durham, North Carolina, United States, 27703